{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=57",
    "query": {
      "intervention": "Open Label Extension Study",
      "page": 57
    },
    "page_size": 10
  },
  "pagination": {
    "page": 57,
    "page_size": 10,
    "total_count": 2085,
    "total_pages": 209,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=58&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=56&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-06T18:34:27.590Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02614261",
      "title": "Evaluation of Galcanezumab in the Prevention of Chronic Migraine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Migraine"
      ],
      "interventions": [
        {
          "name": "Galcanezumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 1117,
      "start_date": "2015-11-30",
      "completion_date": "2021-07-14",
      "has_results": true,
      "last_update_posted_date": "2022-05-18",
      "last_synced_at": "2026-11-06T18:34:27.590Z",
      "location_count": 52,
      "location_summary": "Phoenix, Arizona • Encino, California • Fullerton, California + 47 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02614261"
    },
    {
      "nct_id": "NCT06929273",
      "title": "A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bipolar Disorder Type I With Mania"
      ],
      "interventions": [
        {
          "name": "KarXT",
          "type": "DRUG"
        },
        {
          "name": "Lithium",
          "type": "DRUG"
        },
        {
          "name": "Valproate",
          "type": "DRUG"
        },
        {
          "name": "Lamotrigine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 450,
      "start_date": "2025-07-18",
      "completion_date": "2028-06-13",
      "has_results": false,
      "last_update_posted_date": "2026-10-26",
      "last_synced_at": "2026-11-06T18:34:27.590Z",
      "location_count": 61,
      "location_summary": "Glendale, Arizona • Scottsdale, Arizona • Tucson, Arizona + 49 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Bentonville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06929273"
    },
    {
      "nct_id": "NCT05976243",
      "title": "A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Inducible Urticaria"
      ],
      "interventions": [
        {
          "name": "Remibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 362,
      "start_date": "2023-12-07",
      "completion_date": "2029-06-15",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-11-06T18:34:27.590Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05976243"
    },
    {
      "nct_id": "NCT03497975",
      "title": "PRISM Study-Pruritus Relief Through Itch Scratch Modulation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Prurigo Nodularis"
      ],
      "interventions": [
        {
          "name": "Nalbuphine ER Tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo Tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Trevi Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 353,
      "start_date": "2018-08-07",
      "completion_date": "2023-02-24",
      "has_results": true,
      "last_update_posted_date": "2025-06-24",
      "last_synced_at": "2026-11-06T18:34:27.590Z",
      "location_count": 36,
      "location_summary": "Phoenix, Arizona • Fremont, California • Laguna Niguel, California + 32 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Laguna Niguel",
          "state": "California"
        },
        {
          "city": "North Hollywood",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03497975"
    },
    {
      "nct_id": "NCT03225287",
      "title": "Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Paroxysmal Nocturnal Hemoglobinuria (PNH)"
      ],
      "interventions": [
        {
          "name": "Zilucoplan (RA101495)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ra Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2017-07-17",
      "completion_date": "2021-10-26",
      "has_results": true,
      "last_update_posted_date": "2023-09-28",
      "last_synced_at": "2026-11-06T18:34:27.590Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Dallas, Texas",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03225287"
    },
    {
      "nct_id": "NCT02015234",
      "title": "12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Fibromyalgia"
      ],
      "interventions": [
        {
          "name": "TNX-102 SL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tonix Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 158,
      "start_date": "2013-12",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2017-07-07",
      "last_synced_at": "2026-11-06T18:34:27.590Z",
      "location_count": 13,
      "location_summary": "Denver, Colorado • Brooksville, Florida • Orlando, Florida + 10 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Brooksville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Frederick",
          "state": "Maryland"
        },
        {
          "city": "North Dartmouth",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02015234"
    },
    {
      "nct_id": "NCT03604198",
      "title": "Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cushing Syndrome"
      ],
      "interventions": [
        {
          "name": "relacorilant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corcept Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 125,
      "start_date": "2018-05-07",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-06T18:34:27.590Z",
      "location_count": 25,
      "location_summary": "Phoenix, Arizona • Stanford, California • Torrance, California + 21 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03604198"
    },
    {
      "nct_id": "NCT06941844",
      "title": "A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "DT120",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Definium Therapeutics US, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 149,
      "start_date": "2025-04-14",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-11-06T18:34:27.590Z",
      "location_count": 22,
      "location_summary": "Little Rock, Arkansas • La Jolla, California • Santa Monica, California + 17 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06941844"
    },
    {
      "nct_id": "NCT01151098",
      "title": "Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Nonmalignant Pain"
      ],
      "interventions": [
        {
          "name": "Buprenorphine transdermal patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Purdue Pharma LP",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 189,
      "start_date": "2001-04",
      "completion_date": "2002-02",
      "has_results": true,
      "last_update_posted_date": "2012-09-10",
      "last_synced_at": "2026-11-06T18:34:27.590Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • Trumbull, Connecticut • Clearwater, Florida + 16 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Trumbull",
          "state": "Connecticut"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01151098"
    },
    {
      "nct_id": "NCT00427011",
      "title": "A Study of E2007 In Patients With Parkinson's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "E2007",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2007-02",
      "completion_date": "2008-04",
      "has_results": true,
      "last_update_posted_date": "2013-02-11",
      "last_synced_at": "2026-11-06T18:34:27.590Z",
      "location_count": 9,
      "location_summary": "Peoria, Arizona • Little Rock, Arkansas • Oxnard, California + 6 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Delray Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00427011"
    }
  ]
}